Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions

BridgeBio Pharma, Inc. (NASDAQ: BBIO), and the University of California, San Diego (UC San Diego) today announced a partnership to translate research in genetically driven conditions into potential therapeutic...

BBIO : 55.15 (+0.05%)
BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases

BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with the University of California, Davis (UC Davis), to advance research and the development of investigational medicines for patients...

BBIO : 55.15 (+0.05%)
BridgeBio Pharma, Inc. and Roswell Park Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Cancers

BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Roswell Park Comprehensive Cancer Center to advance the development of investigational therapeutics for patients with genetically...

BBIO : 55.15 (+0.05%)
BridgeBio Pharma, Inc. and Oregon Health & Science University Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Diseases

BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Oregon Health & Science University (OHSU) in Portland, Oregon, to advance research and the development of investigational medicines...

BBIO : 55.15 (+0.05%)
BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers

BridgeBio Pharma, Inc. (NASDAQ: BBIO) and The Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center today announced a collaboration to translate research in genetically driven...

BBIO : 55.15 (+0.05%)
BridgeBio Pharma, Inc. and GlycoNet Initiate Collaboration to Discover Potential Treatments for Genetic Diseases through Glycomics Research

BridgeBio Pharma, Inc. (NASDAQ: BBIO) and the Canadian Glycomics Network (GlycoNet), a pan-Canadian Network of Centres of Excellence, today announced a collaboration to translate scientific research in...

BBIO : 55.15 (+0.05%)
BridgeBio Pharma and Brown University Announce Partnership to Drive the Advancement of Academic Innovations in Genetically Driven Diseases into Potential Therapeutics for Patients

BridgeBio Pharma, Inc. (NASDAQ: BBIO), and Brown University today announced a formal collaboration to advance research in genetically driven neurological disorders into potential life-changing medicines...

BBIO : 55.15 (+0.05%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on April 5, 2021, the compensation committee of BridgeBio's board of...

BBIO : 55.15 (+0.05%)
BridgeBio Pharma's Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology

- BridgeBio, through its affiliate QED ("BridgeBio"), and Helsinn to co-commercialize infigratinib for oncology and all other indications other than skeletal dysplasia indications in the U.S. and equally...

BBIO : 55.15 (+0.05%)
BridgeBio Pharma Announces Proof-of-Concept Data of Encaleret in ADH1 at the Endocrine Society's 2021 Annual Meeting

- Normalization of Blood Calcium and Urine Calcium in 6 of 6 (100%) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Participants Initially Evaluated Over 5 Days Demonstrates Proof-of-Concept

BBIO : 55.15 (+0.05%)
NASDAQ Down for 2021 as Stocks Drop for a Third Day

NASDAQ Down for 2021 as Stocks Drop for a Third Day

SQ : 247.00 (-3.55%)
SPLK : 133.64 (-0.45%)
SHOP : 1,174.15 (-2.79%)
NVAX : 218.02 (-4.10%)
TTD : 697.13 (-3.02%)
EBAY : 64.51 (-0.65%)
XOM : 56.03 (-1.11%)
CVX : 102.33 (-0.61%)
MTDR : 23.67 (-1.29%)
DBC : 17.44 (+0.06%)
BBIO : 55.15 (+0.05%)
LNTH : 21.31 (-1.80%)
WMB : 23.43 (-0.80%)
SLV : 24.00 (-0.37%)
GLD : 166.28 (-0.04%)
MUSA : 141.33 (-1.04%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 1, 2021, the compensation committee of BridgeBio's board of...

BBIO : 55.15 (+0.05%)
BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY(TM) (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A

Molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly, results in severe and largely irreversible neurological injury, and has a high infant...

BBIO : 55.15 (+0.05%)
Is a Surprise Coming for BridgeBio Pharma (BBIO) This Earnings Season?

BridgeBio Pharma (BBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BBIO : 55.15 (+0.05%)
BridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -17.44% and -99.21%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

BBIO : 55.15 (+0.05%)
BridgeBio Pharma: 4Q Earnings Snapshot

PALO ALTO, Calif. (AP) _ BridgeBio Pharma Inc. (BBIO) on Thursday reported a loss of $120 million in its fourth quarter.

BBIO : 55.15 (+0.05%)
BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update

-Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory approval...

BBIO : 55.15 (+0.05%)
EIDX : 122.21 (-4.85%)
BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society's 2021 Annual Meeting

BridgeBio Pharma, Inc. (Nasdaq: BBIO),�?�a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers...

BBIO : 55.15 (+0.05%)
Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BBIO : 55.15 (+0.05%)
Stocks Still Near All-Time Highs Despite Sluggish Week

Stocks Still Near All-Time Highs Despite Sluggish Week

NUS : 52.76 (-0.43%)
BBIO : 55.15 (+0.05%)
MCFT : 26.63 (-2.67%)
MNKD : 4.12 (-1.44%)
TVTX : 24.44 (-2.04%)
AIMC : 61.92 (-1.64%)
FISV : 125.18 (+0.07%)
BTG : 5.02 (-1.76%)
AAWW : 66.60 (-0.40%)

Barchart Exclusives

Raise a Glass to Heineken- This Week in Food&Bev [4/19-4/24]
All the headlines in Food&Bev this week Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar